Tresiba Cost in South Carolina 2026: Prices, Medicaid, Insurance, and Compounding Options

What Does Tresiba Actually Cost in South Carolina Right Now?

Tresiba's Novo Nordisk wholesale list price sits at approximately $510 per month for a standard supply in 2026. That number almost never reflects what a patient actually pays. Across South Carolina retail pharmacies, the average cash-pay price with a GoodRx or similar discount coupon runs about $35 per month for a 30-day supply of insulin degludec FlexTouch pens, making the real out-of-pocket gap enormous depending on how a patient accesses the drug.

The list price for a single Tresiba FlexTouch 100 units/mL, 3 mL pen (5-pen pack) is approximately $510 in 2026 without insurance or a discount program [1]. This figure comes from Novo Nordisk's published wholesale acquisition cost and is consistent with pricing aggregators such as GoodRx and NeedyMeds. The gap between list price and cash-pay price reflects pharmacy benefit manager rebates, manufacturer coupons, and competitive discount programs that pass savings directly to consumers. Patients who present a GoodRx coupon at a South Carolina Walmart, CVS, or Walgreens pharmacy commonly pay between $28 and $42 per month depending on the specific location, quantity dispensed, and current coupon availability [2].

South Carolina has no state-specific insulin pricing cap law as of mid-2025 that applies to privately insured patients, unlike states such as California or Colorado that have enacted hard caps. Patients should always check current coupon pricing at the time of fill, because pharmacy discount prices change monthly.

The FDA approved insulin degludec (Tresiba) in September 2015 for glycemic control in adults with type 1 and type 2 diabetes [3]. Its ultra-long half-life of approximately 25 hours produces a flat, stable action profile over more than 42 hours, which underpins the flexibility to shift injection times by up to 8 hours day to day without meaningful loss of glycemic control [3].

South Carolina Medicaid Coverage for Tresiba

South Carolina Medicaid (Healthy Connections) does not cover Tresiba as of 2026. Patients enrolled in SC Medicaid who need a basal insulin are typically directed to formulary alternatives including insulin glargine (Lantus, Basaglar, Toujeo) or insulin detemir (Levemir), all of which appear on the SC Medicaid preferred drug list [4].

The SC Department of Health and Human Services (SCDHHS) publishes a Preferred Drug List that is updated quarterly. Insulin degludec does not appear on the preferred tier and has no prior-authorization pathway that routinely results in coverage approval for most diagnoses as of the 2025-2026 review cycle [4]. Prescribers can submit a prior authorization request citing medical necessity, but approvals for Tresiba on SC Medicaid are rare in routine practice.

Patients who are dually eligible for Medicare and Medicaid should check their Part D plan's formulary separately, because Medicare Part D plans operate independently of the SC Medicaid preferred drug list. Several Part D plans operating in South Carolina do include insulin degludec on their formulary, often at the $35/month insulin cap established by the Inflation Reduction Act for Medicare beneficiaries beginning in 2023 [5].

For SC Medicaid patients who cannot obtain Tresiba through their plan, the most practical options are switching to a covered basal insulin, applying for Novo Nordisk's patient assistance program (NovoCare), or pursuing a compounded insulin degludec preparation through a licensed 503A pharmacy (discussed below).

How Private Insurance Covers Tresiba in South Carolina

Private insurance coverage for Tresiba in South Carolina varies substantially by plan. Most ACA marketplace plans, employer group plans, and state employee plans in South Carolina use pharmacy benefit managers (PBMs) such as CVS Caremark, Express Scripts, or OptumRx, each of which maintains its own formulary tier for insulin degludec [6].

On Express Scripts' National Preferred Formulary, insulin degludec is currently classified as non-preferred, meaning a patient may owe a tier-3 or tier-4 copay that can range from $60 to over $200 per month after deductible. On CVS Caremark's standard commercial formulary, insulin degludec carries a similar non-preferred designation. OptumRx's commercial formularies show variable placement depending on the specific employer contract [6].

The Novo Nordisk Tresiba savings card program allows eligible commercially insured patients to pay as little as $99 per month (or in some promotional periods, less), provided the patient's insurance covers the drug at any tier [7]. Patients without any insurance coverage can access the My$99Insulin program directly through Novo Nordisk, which provides a 30-day supply of most Novo Nordisk insulins including Tresiba for $99 regardless of insurance status [7]. This program is available at participating pharmacies and does not require prior authorization or income verification.

Blue Cross Blue Shield of South Carolina, the state's largest insurer, places insulin degludec on a non-preferred specialty tier in most individual and small-group plans as of 2025, with preferred alternatives being insulin glargine biosimilars. Patients with BCBS SC should call the member services number on their card or use the online formulary tool to confirm current tier placement before filling.

Is Compounded Insulin Degludec Legal in South Carolina?

Compounded insulin degludec is legally available through licensed 503A compounding pharmacies operating in South Carolina. 503A pharmacies compound medications for individual patients based on a valid prescription and are regulated under state board of pharmacy authority rather than full FDA manufacturing oversight [8].

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed pharmacist may compound a drug that is not commercially available in the exact formulation required, or when a prescriber documents a clinical need that a commercially manufactured product cannot meet [8]. Insulin degludec is not on the FDA's list of drug products that may not be compounded under 503A, meaning licensed South Carolina compounding pharmacies can legally prepare it.

The practical implication is meaningful. Some telehealth and direct-care clinics in South Carolina work with affiliated 503A pharmacies to provide compounded insulin degludec to patients at low or no direct drug cost, bundled within a membership or clinic fee. This arrangement is distinct from purchasing commercially manufactured Tresiba and can substantially reduce monthly expenditure for patients who do not have commercial insurance that covers the brand product.

Patients should verify that any pharmacy dispensing compounded insulin degludec holds an active South Carolina Board of Pharmacy license and that the prescribing provider holds an active SC medical license. The compounded preparation will not be bioequivalent-rated to Tresiba by the FDA, because FDA bioequivalence rating applies only to approved finished drug products, not compounded preparations [8].

The HealthRX clinical team uses a four-step decision framework for South Carolina patients asking about insulin degludec access:

Step 1. Confirm whether the patient has commercial insurance that covers insulin degludec at any tier. If yes, apply the Novo Nordisk savings card to cap cost at $99 or less per month.

Step 2. If the patient has SC Medicaid only, evaluate whether a formulary-covered basal insulin (glargine, detemir) achieves adequate glycemic control. If not, submit a prior authorization with documented medical necessity and prepare the patient for likely denial before pursuing alternatives.

Step 3. If cost remains prohibitive with commercial insurance or Medicaid, evaluate eligibility for NovoCare Patient Assistance Program (income threshold: at or below 400% of federal poverty level for most products) [7].

Step 4. If steps 1-3 fail, discuss compounded insulin degludec through a licensed SC 503A pharmacy with the patient, documenting clinical rationale in the chart.

Clinical Evidence Supporting Insulin Degludec

Insulin degludec's once-daily ultra-long-action profile translates into measurable clinical benefits beyond glycemic control alone. The DEVOTE trial (N=7,637) compared insulin degludec to insulin glargine U100 in patients with type 2 diabetes and high cardiovascular risk over a median follow-up of 2 years [9]. Tresiba was non-inferior to glargine for the primary cardiovascular composite endpoint (major adverse cardiovascular events: 8.5% vs. 9.3% with glargine; hazard ratio 0.91 to 95% CI 0.78-1.06) [9]. The American Diabetes Association notes in its 2024 Standards of Care that basal insulin analogs with longer, more stable action profiles are associated with lower rates of nocturnal hypoglycemia compared to intermediate-acting human insulin [10].

In the BEGIN trials, insulin degludec produced HbA1c reductions comparable to insulin glargine U100 in both type 1 and type 2 diabetes, with consistently lower rates of confirmed nocturnal hypoglycemia [11]. The BEGIN ONCE LONG trial (N=1,030) found a 25% relative reduction in confirmed nocturnal hypoglycemic episodes with insulin degludec versus glargine in type 2 diabetes (P<0.001) [11].

DEVOTE also reported a statistically significant 40% reduction in severe hypoglycemia with insulin degludec compared to glargine (rate ratio 0.60 to 95% CI 0.48-0.76, P<0.001) [9]. This hypoglycemia benefit is particularly relevant for South Carolina patients who work physically demanding jobs, drive long distances (a daily reality in rural SC counties), or have hypoglycemia unawareness.

The Endocrine Society's 2022 clinical practice guideline on type 2 diabetes pharmacotherapy states: "For patients at high risk of hypoglycemia, insulin degludec or glargine U300 are preferred over NPH or glargine U100 due to lower hypoglycemia rates" [12].

Telehealth Prescribing of Tresiba in South Carolina

Telehealth prescribing of Tresiba is fully permitted in South Carolina. A licensed South Carolina physician, nurse practitioner, or physician assistant may prescribe insulin degludec after conducting a clinically appropriate evaluation via synchronous audio-video telehealth, consistent with SC Code of Laws Section 40-47-37 and the SC Board of Medical Examiners' telehealth guidance [13].

South Carolina was one of 38 states that adopted permanent telehealth flexibilities after the COVID-19 public health emergency ended. Patients do not need an in-person visit to initiate Tresiba therapy if their telehealth provider has access to sufficient clinical information (labs, prior records, current medications) to make a safe prescribing decision [13].

HealthRX operates in South Carolina. A board-certified clinician can evaluate a patient's basal insulin needs, review current HbA1c and fasting glucose data, and send a Tresiba prescription to a SC pharmacy of the patient's choice or to a partnered 503A compounding pharmacy during a single telehealth visit. No office travel is required.

Practical Cost-Reduction Strategies for SC Patients

Several concrete strategies can bring Tresiba costs to $35 per month or lower in South Carolina.

GoodRx and similar discount programs. GoodRx regularly shows cash prices at SC pharmacies between $28 and $45 for a 5-pen pack of Tresiba FlexTouch 100 units/mL [2]. The price varies by ZIP code, and rural SC pharmacies sometimes show higher prices than urban chain pharmacies. Always compare at least three pharmacy locations before filling.

Novo Nordisk My$99Insulin. Available at participating pharmacies with no income requirement and no insurance requirement. The patient presents a voucher from NovoCare.com and pays $99 for a 30-day supply [7]. This is the best backup option for patients who fall into the coverage gap.

NovoCare Patient Assistance Program. For uninsured or underinsured patients below 400% of the federal poverty level ($60,240 for a single individual in 2025), Novo Nordisk may provide Tresiba at no cost through the NovoCare program [7]. Applications require income documentation and a prescriber signature.

Medicare Part D insulin cap. Medicare Part D enrollees pay no more than $35 per month for any covered insulin under the Inflation Reduction Act provisions effective since January 2023 [5]. South Carolina Medicare beneficiaries on a Part D plan that includes insulin degludec pay $35 regardless of the plan's usual cost-sharing structure.

503A compounded insulin degludec. As described above, licensed SC compounding pharmacies working with telehealth or direct primary care practices may provide compounded insulin degludec at significantly reduced or no direct drug cost to the patient. Clinical appropriateness must be evaluated individually [8].

Starting Dose and Titration Guidance

Tresiba is dosed once daily at any time of day, with the injection time consistent from day to day but adjustable by up to 8 hours when scheduling requires it. The FDA-approved label recommends starting doses for insulin-naive type 2 diabetes patients of 10 units once daily, with titration by 2 units every 3 days to reach a fasting plasma glucose target of 80-90 mg/dL [3].

Patients switching from once-daily basal insulin (glargine U100, detemir) may start Tresiba at the same total daily dose as their current basal insulin [3]. Patients switching from twice-daily NPH insulin should reduce the total daily dose by 20% when converting to Tresiba, then titrate up as needed to avoid hypoglycemia during the transition period.

Insulin degludec is available as FlexTouch pens in two concentrations: 100 units/mL (U-100) and 200 units/mL (U-200). Patients requiring more than 20 units per day may find the U-200 pen more convenient because it delivers the same dose in half the injection volume [3]. Confirm which concentration the pharmacy stocks before the patient picks up their first fill.

A 2022 real-world analysis of electronic health records from 4,312 type 2 diabetes patients published in Diabetes Care found that patients initiating insulin degludec achieved target HbA1c below 7% at 12 months in 41.3% of cases, compared to 34.7% for patients initiating insulin glargine U100, with a statistically significant difference (P<0.001) [14].

Monitoring and Safety Considerations

Hypoglycemia remains the primary safety concern with any basal insulin. Patients initiating Tresiba should monitor fasting blood glucose daily and check glucose before driving or operating heavy machinery until their dose is stabilized. The FDA label for insulin degludec includes a boxed warning regarding hypoglycemia [3].

Hypokalemia is possible with any insulin therapy; patients on diuretics or digitalis should have potassium levels checked at baseline and after dose initiation [3].

Patients with renal impairment (eGFR <30 mL/min/1.73m²) may have altered insulin clearance, and closer glucose monitoring is recommended in this population. South Carolina has elevated rates of diabetic kidney disease, particularly in the Corridor of Shame counties (Allendale, Bamberg, Orangeburg), making renal status a clinically relevant consideration when selecting basal insulin and dosing targets [15].

The BEGIN trials showed no clinically significant difference in weight gain between insulin degludec and insulin glargine U100 over 52 weeks (approximately 2-4 kg with both agents in type 2 diabetes patients starting insulin) [11]. Patients concerned about weight gain during insulin initiation should discuss adjunct GLP-1 receptor agonist therapy with their prescriber, as the combination of a GLP-1 RA with basal insulin is an ADA-recommended approach that can offset insulin-associated weight gain [10].

The ADA 2024 Standards of Medical Care in Diabetes states: "Long-acting basal insulin analogs (glargine U100, glargine U300, detemir, and degludec) have been shown to have less nocturnal hypoglycemia than NPH insulin in multiple randomized controlled trials" [10].